References
- Laizure SC , ParkerRB, HerringVL, HuZY. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metabol. Dispos. 42 (2), 201–206 (2014).
- Stangier J , RathgenK, StahleH, GansserD, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 64 (3), 292–303 (2007).
- Ebner T , WagnerK, WienenW. Dabigatran acylglucuronide, the major human metabolite of dabigatran: In vitro formation, stability, and pharmacological activity. Drug Metabol. Dispos. 38 (9), 1567–1575 (2010).
- Regan SL , MaggsJL, HammondTG, LambertC, WilliamsDP, ParkBK. Acyl glucuronides: The good, the bad and the ugly. Biopharm. Drug Dispos. 31 (7), 367–395 (2010).
- Horng H , Spahn-LangguthH, BenetLZ. Mechanistic role of acyl glucuronides. In : Drug-Induced Liver Disease. Academic Press, Amsterdam, 35–70 (2013).
- Xue YJ , AkinsanyaJB, RaghavanN, ZhangD. Optimization to eliminate the interference of migration isomers for measuring 1-O-β-acyl glucuronide without extensive chromatographic separation. Rapid Commun. Mass Spectrom. 22 (2), 109–120 (2008).
- Ketola RA , HakalaKS. Direct analysis of glucuronides with liquid chromatography-mass spectrometric techniques and methods. Curr. Drug Metabol. 11 (7), 561–582 (2010).
- Douxfils J , DogneJM, MullierFet al. Comparison of calibrated dilute thrombin time and aPTT tests with LC–MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb. Haemost. 110 (3), 543–549 (2013).
- Härtter S , Koenen-BergmannM, SharmaAet al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol. 74 (3), 490–500 (2012).
- Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). (2001). www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
- Gous T , CouchmanL, PatelJP, ParadzaiC, AryaR, FlanaganRJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther. Drug Monit. 36 (5), 597–605 (2014).
- Delavenne X , MoracchiniJ, LaporteS, MismettiP, BassetT. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J. Pharm. Biomed. Anal. 58 (1), 152–156 (2012).
- Korostelev M , BihanK, FerreolLet al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. (2014).
- Schmitz EMH , BoonenK, van den HeuvelDJAet al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC–MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J. Thromb. Haemost. 12 (10), 1636–1646 (2014).
- Stangier J , StähleH, RathgenK, RothW, ReseskiK, KörnickeT. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J. Clin. Pharmacol. 52 (2), 243–250 (2012).
- Côté C , LahaieM, LatourSet al. Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation: ramiprilat case study. Bioanalysis3 (9), 951–965 (2011).
- Silvestro L , GheorgheM, IordachescuAet al. Development and validation of an HPLC–MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal. Bioanal. Chem. 401 (3), 1023–1034 (2011).
- Stachulski AV . Chemistry and reactivity of acyl glucuronides. Curr. Drug Metabol. 12 (3), 215–221 (2011).
- Tan A , JinW, DengF, HussainS, MusukuA, MasséR. Bioanalytical method development and validation using incurred samples-Simultaneous quantitation of ramipril and ramiprilat in human EDTA plasma by LC–MS/MS. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 877 (29), 3673–3680 (2009).
- Stangier J , RathgenK, StahleH, MazurD. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49 (4), 259–268 (2010).